The field of psychiatry is hampered by a lack of robust, reliable and valid biomarkers that can
aid in objectively diagnosing patients and providing individualized treatment …

Despite a lack of recent progress in the treatment of schizophrenia, our understanding of its
genetic and environmental causes has considerably improved, and their relationship to …

Schizophrenia is a complex neuropsychiatric disorder that is associated with persistent
psychosocial disability in affected individuals. Although studies of schizophrenia have …

Background The observation that mismatch negativity (MMN) is consistently impaired in
schizophrenia has generated considerable interest in the use of this biomarker as an index …

Sensory processing deficits, first investigated by Kraepelin and Bleuler as possible
pathophysiological mechanisms in schizophrenia, are now being recharacterized in the …

Cannabis is the most commonly used illicit drug worldwide, with~ 5 million daily users
worldwide. Emerging evidence supports a number of associations between cannabis and …

Scientific progress in understanding human disease can be measured by the effectiveness
of its treatment. Antipsychotic drugs have been proven to alleviate acute psychotic symptoms …

Human ratings of conceptual disorganization, poverty of content, referential cohesion and
illogical thinking have been shown to predict psychosis onset in prospective clinical high risk …

Introduction: Electrophysiological (EEG) abnormalities in subjects with schizophrenia have
been largely reported. In the last decades, research has shifted to the identification of …

Cognition is often affected in a variety of neuropsychiatric, neurological, and
neurodevelopmental disorders. The neural discriminative response, reflected in mismatch …